First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors.
Journal
Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676
Informations de publication
Date de publication:
13 Jan 2024
13 Jan 2024
Historique:
received:
31
03
2023
accepted:
04
01
2024
medline:
14
1
2024
pubmed:
14
1
2024
entrez:
13
1
2024
Statut:
epublish
Résumé
VT1021 is a cyclic peptide that induces the expression of thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs) recruited to the tumor microenvironment (TME). TSP-1 reprograms the TME via binding to CD36 and CD47 to induce tumor and endothelial cell apoptosis as well as immune modulation in the TME. Study VT1021-01 (ClinicalTrials.gov ID NCT03364400) used a modified 3 + 3 design. The primary objective was to determine the recommended Phase 2 dose (RP2D) in patients with advanced solid tumors. Safety, tolerability, and pharmacokinetics (PK) were assessed. Patients were dosed twice weekly intravenously in 9 cohorts (0.5-15.6 mg/kg). Safety was evaluated using CTCAE version 5.0 and the anti-tumor activity was evaluated by RECIST version 1.1. The RP2D of VT1021 is established at 11.8 mg/kg. VT1021 is well tolerated with no dose-limiting toxicities reported (0/38). The most frequent drug-related adverse events are fatigue (15.8%), nausea (10.5%), and infusion-related reactions (10.5%). Exposure increases proportionally from 0.5 to 8.8 mg/kg. The disease control rate (DCR) is 42.9% with 12 of 28 patients deriving clinical benefit including a partial response (PR) in one thymoma patient (504 days). VT1021 is safe and well-tolerated across all doses tested. RP2D has been selected for future clinical studies. PR and SD with tumor shrinkage are observed in multiple patients underscoring the single-agent potential of VT1021. Expansion studies in GBM, pancreatic cancer and other solid tumors at the RP2D have been completed and results will be communicated in a separate report. It may be possible to treat cancers with therapies that modify the tumor microenvironment. This is the environment in the body in which tumors survive and grow and is composed of different types of cells. One such potential therapy is VT1021. Here, we conduct the first clinical trial to test this therapy in patients. We identify the optimal dose of the treatment to take into further studies, finding that VT1021 is safe and well tolerated by patients. We see some signs that the treatment is working in some patients and see evidence of modification of the tumor microenvironment. These findings help to inform further clinical trials of VT1021 to determine whether it is safe and effective in larger cohorts of patients.
Sections du résumé
BACKGROUND
BACKGROUND
VT1021 is a cyclic peptide that induces the expression of thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs) recruited to the tumor microenvironment (TME). TSP-1 reprograms the TME via binding to CD36 and CD47 to induce tumor and endothelial cell apoptosis as well as immune modulation in the TME.
METHODS
METHODS
Study VT1021-01 (ClinicalTrials.gov ID NCT03364400) used a modified 3 + 3 design. The primary objective was to determine the recommended Phase 2 dose (RP2D) in patients with advanced solid tumors. Safety, tolerability, and pharmacokinetics (PK) were assessed. Patients were dosed twice weekly intravenously in 9 cohorts (0.5-15.6 mg/kg). Safety was evaluated using CTCAE version 5.0 and the anti-tumor activity was evaluated by RECIST version 1.1.
RESULTS
RESULTS
The RP2D of VT1021 is established at 11.8 mg/kg. VT1021 is well tolerated with no dose-limiting toxicities reported (0/38). The most frequent drug-related adverse events are fatigue (15.8%), nausea (10.5%), and infusion-related reactions (10.5%). Exposure increases proportionally from 0.5 to 8.8 mg/kg. The disease control rate (DCR) is 42.9% with 12 of 28 patients deriving clinical benefit including a partial response (PR) in one thymoma patient (504 days).
CONCLUSIONS
CONCLUSIONS
VT1021 is safe and well-tolerated across all doses tested. RP2D has been selected for future clinical studies. PR and SD with tumor shrinkage are observed in multiple patients underscoring the single-agent potential of VT1021. Expansion studies in GBM, pancreatic cancer and other solid tumors at the RP2D have been completed and results will be communicated in a separate report.
It may be possible to treat cancers with therapies that modify the tumor microenvironment. This is the environment in the body in which tumors survive and grow and is composed of different types of cells. One such potential therapy is VT1021. Here, we conduct the first clinical trial to test this therapy in patients. We identify the optimal dose of the treatment to take into further studies, finding that VT1021 is safe and well tolerated by patients. We see some signs that the treatment is working in some patients and see evidence of modification of the tumor microenvironment. These findings help to inform further clinical trials of VT1021 to determine whether it is safe and effective in larger cohorts of patients.
Autres résumés
Type: plain-language-summary
(eng)
It may be possible to treat cancers with therapies that modify the tumor microenvironment. This is the environment in the body in which tumors survive and grow and is composed of different types of cells. One such potential therapy is VT1021. Here, we conduct the first clinical trial to test this therapy in patients. We identify the optimal dose of the treatment to take into further studies, finding that VT1021 is safe and well tolerated by patients. We see some signs that the treatment is working in some patients and see evidence of modification of the tumor microenvironment. These findings help to inform further clinical trials of VT1021 to determine whether it is safe and effective in larger cohorts of patients.
Identifiants
pubmed: 38218979
doi: 10.1038/s43856-024-00433-x
pii: 10.1038/s43856-024-00433-x
doi:
Banques de données
ClinicalTrials.gov
['NCT03364400']
Types de publication
Journal Article
Langues
eng
Pagination
10Informations de copyright
© 2024. The Author(s).
Références
Chen, F. et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med. 5, 45 (2015).
doi: 10.1186/s12916-015-0278-7
McAllister, S. & Weinberg, R. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat. Cell Biol. 16, 717–727 (2014).
doi: 10.1038/ncb3015
pubmed: 25082194
De Fraipont, F., Nicholson, A., Feige, J. & Van Meir, E. Thrombospondins and tumor angiogenesis. Trends Mol. Med. 7, 401–407 (2001).
doi: 10.1016/S1471-4914(01)02102-5
pubmed: 11530335
Catena, R. et al. Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov. 3, 578–589 (2013).
doi: 10.1158/2159-8290.CD-12-0476
pubmed: 23633432
pmcid: 3672408
Alvarez, A. et al. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. Gynecol. Oncol. 82, 273–278 (2001).
doi: 10.1006/gyno.2001.6287
pubmed: 11531279
Kang, S. et al. Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc. Natl Acad. Sci. USA 106, 12115–12120 (2009).
doi: 10.1073/pnas.0903120106
pubmed: 19581582
Wang, S. et al. Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. Sci. Transl. Med. 8, 329ra34 (2016).
doi: 10.1126/scitranslmed.aad5653
pubmed: 26962158
pmcid: 6261358
Kuemmerle, N. et al. Lipoprotein lipase links dietary fat to solid tumor cell proliferation. Mol. Cancer Ther. 10, 427–436 (2011).
doi: 10.1158/1535-7163.MCT-10-0802
pubmed: 21282354
pmcid: 3074101
Gao, L. et al. CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis. Oncotarget 8, 22406–22413 (2017).
doi: 10.18632/oncotarget.9899
pubmed: 27283989
Jaiswal, S. et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271–285 (2009).
doi: 10.1016/j.cell.2009.05.046
pubmed: 19632178
pmcid: 2775564
Enciu, A., Radu, E., Popescu, I., Hinescu, M. & Ceafalan, L. Targeting CD36 as biomarker for metastasis prognostic: how far from translation into clinical practice?. Biomed. Res. Int. 2018, 7801202 (2018).
doi: 10.1155/2018/7801202
pubmed: 30069479
pmcid: 6057354
Huang, C., Ye, Z., Huang, M. & Lu, J. Regulation of CD47 expression in cancer cells. Transl. Oncol. 13, 100862 (2020).
doi: 10.1016/j.tranon.2020.100862
pubmed: 32920329
pmcid: 7494507
Keren, L. et al. MIBI-TOF: a multiplexed imaging platform relates cellular phenotypes and tissue structure. Sci. Adv. 5, eaax5851 (2019).
doi: 10.1126/sciadv.aax5851
pubmed: 31633026
pmcid: 6785247
Schulz, K. F., Altman, D. G. & Moher, D. CONSORT 2010 Statement. BMJ 340, c332 (2010)
Tanase, C. et al. Fatty acids, CD36, Thrombospondin-1, and CD47 in glioblastoma: together and/or separately? Int. J. Mol. Sci. 23, 1 (2022).
doi: 10.3390/ijms23020604
Timmer, F. et al. Pancreatic cancer and immunotherapy: a clinical overview. Cancers 13, 4138 (2021).
doi: 10.3390/cancers13164138
pubmed: 34439292
pmcid: 8393975
Ebbinghaus, S. et al. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin. Cancer Res. 13, 6689 (2007).
doi: 10.1158/1078-0432.CCR-07-1477
pubmed: 18006769
Baker, L. et al. Randomized, phase II study of the thrombospondin-1- mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J. Clin. Oncol. 26, 5583 (2008).
doi: 10.1200/JCO.2008.17.4706
pubmed: 18981463
Wang, J. & Li, Y. CD36 tango in cancer: signaling pathways and functions. Theranostics 9, 4893 (2019).
doi: 10.7150/thno.36037
pubmed: 31410189
pmcid: 6691380
Stein, E., Miller, T., Ivins-O’Keefe, Kaur, S. & Roberts, D. Secreted thrombospondin-1 regulates macrophage interleukin-1β production and activation through CD47. Sci. Rep. 6, 1 (2016).
doi: 10.1038/srep19684